Related Experiment Video
Updated: May 8, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
Hepatitis B antivirals and resistance.
1Eastern Health, Victoria, Australia; Research & Molecular Development, Victorian Infectious Diseases Reference Laboratory, 10 Wreckyn St, North Melbourne, VIC 3051, Australia.
Drug-resistant hepatitis B virus (HBV) variants emerge due to antiviral therapy. Careful selection of potent rescue therapies can minimize drug resistance and vaccine escape, improving patient outcomes in chronic hepatitis B (CHB).
Area of Science:
- Hepatology
- Virology
- Infectious Diseases
Background:
- Antiviral therapy has improved outcomes for chronic hepatitis B (CHB).
- Nucleos(t)ide analogue pressure drives the emergence of drug-resistant hepatitis B virus (HBV) variants.
- Overlapping reading frames in the HBV genome contribute to variant emergence.
Purpose of the Study:
- To highlight the clinical and public health implications of drug-resistant HBV variants.
- To emphasize the need for strategic antiviral therapy selection to mitigate resistance and vaccine escape.
- To inform the management of CHB in the era of antiviral resistance.
Main Methods:
- Review of existing literature on HBV antiviral resistance.
- Analysis of the genetic structure of HBV and its impact on variant emergence.
- Discussion of therapeutic strategies for managing drug-resistant HBV infections.
Main Results:
- Drug-resistant HBV variants pose risks including treatment failure and vaccine escape.
- The emergence of these variants is an inevitable consequence of antiviral treatment.
- High genetic barrier and potent antiviral therapies are crucial for effective rescue treatment.
Conclusions:
- While HBV variant emergence cannot be prevented, strategic therapeutic choices are essential.
- Appropriate rescue antiviral therapy can minimize the impact of drug resistance and vaccine escape.
- Effective management strategies are critical for improving long-term outcomes in CHB patients.
More Related Videos
10:37Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix
Published on: October 20, 2021
09:35Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
Published on: February 1, 2017
Related Concept Videos
Hepatitis
Retrovirus Life Cycles
Viral Hepatitis I: Introduction
Treatment Resistant Cancers
Inhibitors of Viral Protein Synthesis
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment